×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Kevin Wright
When compared with Nexavar, Fotivda showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma.
Brielle Benyon
Patients participating in phase 1 clinical trials could benefit from the integration of palliative care, according to data presented at the 2020 ASCO Virtual Scientific Meeting.
Ryan McDonald
“The superior efficacy of venetoclax-obinutuzumab has been observed and maintained in the current follow up,” Dr. Othman Al-Sawaf, of University Hospital of Cologne in Germany, said during a pre-recording presentation at the 2020 ASCO Virtual Scientific Program.
 
Ryan McDonald
“Collectively, these results support acalabrutinib (Calquence) use in upfront CLL,” said Dr. John C. Byrd. “This is compounded and supported by two additional phase III studies that have been completed with this agent.”
 
Brielle Benyon
Results from an early-phase trial showed that cirmtuzumab plus Imbruvica is safe and efficacious in treating patients with relapsed/refractory MCL and CLL.
 
Barbara Fromholz
Beth Fand Incollingo
One survivor has advice for others affected by both cancer and the COVID-19 pandemic: Accept your limitations.
 
Jessica Skarzynski
Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for May 2020.
 
CURE Staff
CURE is hosting its third webinar that will focus on all the latest topics and trends for patients with lung cancer. The webinar will be held Monday, June 8, 2020 8 - 9 p.m. ET. 
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×